Abeona Therapeutics Inc. (0H7R.L)
USD 5.88
(-2.0%)
USD 5.88
(-2.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 49.17 Million USD | 31.3% |
| 2022 | 37.45 Million USD | 32.76% |
| 2021 | 28.21 Million USD | -42.01% |
| 2020 | 48.64 Million USD | 8.22% |
| 2019 | 44.95 Million USD | 11.39% |
| 2018 | 40.35 Million USD | 365.55% |
| 2017 | 8.66 Million USD | -27.53% |
| 2016 | 11.96 Million USD | -3.03% |
| 2015 | 12.33 Million USD | 325.6% |
| 2014 | 2.89 Million USD | -67.66% |
| 2013 | 8.96 Million USD | 35.18% |
| 2012 | 6.62 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 60.76 Million USD | -27.41% |
| 2024 Q1 | 83.7 Million USD | 70.22% |
| 2023 Q3 | 44.04 Million USD | -0.35% |
| 2023 Q1 | 34.6 Million USD | -7.6% |
| 2023 FY | 49.17 Million USD | 31.3% |
| 2023 Q2 | 44.2 Million USD | 27.74% |
| 2023 Q4 | 49.17 Million USD | 11.64% |
| 2022 Q1 | 23.72 Million USD | -15.89% |
| 2022 FY | 37.45 Million USD | 32.76% |
| 2022 Q4 | 37.45 Million USD | 60.41% |
| 2022 Q3 | 23.34 Million USD | -5.22% |
| 2022 Q2 | 24.63 Million USD | 3.81% |
| 2021 FY | 28.21 Million USD | -42.01% |
| 2021 Q1 | 47.04 Million USD | -3.3% |
| 2021 Q3 | 39.27 Million USD | -15.7% |
| 2021 Q4 | 28.21 Million USD | -28.17% |
| 2021 Q2 | 46.58 Million USD | -0.96% |
| 2020 Q1 | 42.62 Million USD | -5.17% |
| 2020 FY | 48.64 Million USD | 8.22% |
| 2020 Q2 | 43.32 Million USD | 1.64% |
| 2020 Q3 | 44.25 Million USD | 2.15% |
| 2020 Q4 | 48.64 Million USD | 9.93% |
| 2019 Q4 | 44.95 Million USD | -3.78% |
| 2019 FY | 44.95 Million USD | 11.39% |
| 2019 Q3 | 46.72 Million USD | -10.58% |
| 2019 Q2 | 52.25 Million USD | 8.08% |
| 2019 Q1 | 48.34 Million USD | 137.51% |
| 2018 Q2 | 5.78 Million USD | -10.4% |
| 2018 FY | 40.35 Million USD | 365.55% |
| 2018 Q1 | 6.45 Million USD | 15.11% |
| 2018 Q4 | 20.35 Million USD | 97.02% |
| 2018 Q3 | 10.33 Million USD | 78.64% |
| 2017 Q1 | 6.06 Million USD | -26.89% |
| 2017 FY | 8.66 Million USD | -27.53% |
| 2017 Q3 | 2.63 Million USD | -37.45% |
| 2017 Q4 | 5.6 Million USD | 112.47% |
| 2017 Q2 | 4.21 Million USD | -30.44% |
| 2016 Q2 | 8.7 Million USD | 13.91% |
| 2016 Q1 | 7.64 Million USD | 417.54% |
| 2016 FY | 11.96 Million USD | -3.03% |
| 2016 Q4 | 8.29 Million USD | 27.34% |
| 2016 Q3 | 6.51 Million USD | -25.18% |
| 2015 Q1 | 1.24 Million USD | -57.21% |
| 2015 FY | 12.33 Million USD | 325.6% |
| 2015 Q4 | 1.47 Million USD | -5.92% |
| 2015 Q3 | 1.57 Million USD | -18.23% |
| 2015 Q2 | 1.92 Million USD | 54.84% |
| 2014 Q1 | 10.04 Million USD | 12.09% |
| 2014 Q2 | 11.17 Million USD | 11.23% |
| 2014 Q3 | 12.61 Million USD | 12.93% |
| 2014 FY | 2.89 Million USD | -67.66% |
| 2014 Q4 | 2.89 Million USD | -77.03% |
| 2013 Q2 | 7.77 Million USD | 0.34% |
| 2013 Q4 | 8.96 Million USD | 11.87% |
| 2013 Q1 | 7.74 Million USD | 16.84% |
| 2013 Q3 | 8.01 Million USD | 3.08% |
| 2013 FY | 8.96 Million USD | 35.18% |
| 2012 FY | 6.62 Million USD | 0.0% |
| 2012 Q4 | 6.62 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | 67.228% |
| Dynavax Technologies Corporation | 375.02 Million USD | 86.887% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 89.912% |
| Perrigo Company plc | 6.04 Billion USD | 99.186% |
| Illumina, Inc. | 4.36 Billion USD | 98.874% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.905% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 74.877% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.929% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.761% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 80.827% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 99.308% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -31.867% |
| Waters Corporation | 3.47 Billion USD | 98.585% |
| Biogen Inc. | 12.04 Billion USD | 99.592% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | 40.344% |
| Evolus, Inc. | 209.68 Million USD | 76.548% |
| Adicet Bio, Inc. | 37.12 Million USD | -32.478% |
| Cara Therapeutics, Inc. | 68.75 Million USD | 28.481% |
| bluebird bio, Inc. | 424.62 Million USD | 88.419% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 92.558% |
| FibroGen, Inc. | 585.72 Million USD | 91.604% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 99.0% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -39.795% |
| Homology Medicines, Inc. | 118.53 Million USD | 58.513% |
| Geron Corporation | 146.12 Million USD | 66.347% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 98.786% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 92.039% |
| Myriad Genetics, Inc. | 312.9 Million USD | 84.284% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -145.01% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 80.393% |
| Zoetis Inc. | 9.29 Billion USD | 99.471% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 98.597% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 97.398% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 99.045% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1.509% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 98.111% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 81.424% |
| Verastem, Inc. | 71.18 Million USD | 30.918% |
| Nektar Therapeutics | 267.04 Million USD | 81.585% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 87.621% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -22.249% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 97.955% |
| OPKO Health, Inc. | 622.47 Million USD | 92.1% |
| Exelixis, Inc. | 678.44 Million USD | 92.752% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 95.176% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | 57.168% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -292.341% |
| uniQure N.V. | 624.01 Million USD | 92.119% |
| Imunon, Inc. | 8.53 Million USD | -476.478% |
| Blueprint Medicines Corporation | 918.64 Million USD | 94.647% |
| Insmed Incorporated | 1.66 Billion USD | 97.041% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 97.019% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 61.002% |
| TG Therapeutics, Inc. | 169.08 Million USD | 70.916% |
| Incyte Corporation | 1.59 Billion USD | 96.912% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 95.852% |